Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

229.43 -0.55 (-0.24%)

Streaming Delayed Price Updated: 3:51 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

August 01, 2025

From Natera, Inc.

Via Business Wire

Natera to Report Its Second Quarter Results on August 7, 2025

July 31, 2025

From Natera, Inc.

Via Business Wire

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

July 29, 2025

From Natera, Inc.

Via Business Wire

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

July 24, 2025

From Natera, Inc.

Via Business Wire

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

July 20, 2025

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades.

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

July 15, 2025

Via Benzinga

1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution

July 08, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

July 07, 2025

From Natera, Inc.

Via Business Wire

1 Growth Stock with Exciting Potential and 2 to Be Wary Of

July 03, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

July 01, 2025

From Natera, Inc.

Via Business Wire

Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)

June 29, 2025

Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season.

Via StockStory

Topics Artificial Intelligence

Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today ↗

June 26, 2025

Via Benzinga

1 Volatile Stock to Own for Decades and 2 to Brush Off

June 26, 2025

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

June 22, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

3 Reasons We Love Natera (NTRA)

June 20, 2025

Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%.

Via StockStory

Topics Government Stocks

Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗

June 13, 2025

Via Benzinga

A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack

June 11, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase

June 10, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue...

Via StockStory

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

Natera Announces Medicare Coverage for Signatera™ Genome

June 04, 2025

From Natera, Inc.

Via Business Wire

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

June 02, 2025

From Natera, Inc.

Via Business Wire

2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of

June 02, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

3 Mid-Cap Stocks Worth Your Attention

May 27, 2025

Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses...

Via StockStory

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

May 26, 2025

Via Benzinga

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 22, 2025

From Natera, Inc.

Via Business Wire

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗

May 12, 2025

Via Benzinga

8 Analysts Have This To Say About Natera ↗

May 09, 2025

Via Benzinga

Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales

May 08, 2025

Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98...

Via StockStory

Natera Reports First Quarter 2025 Financial Results

May 08, 2025

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.